Host Genetics at the Intersection of Autoimmunity and COVID-19: A Potential Key for Heterogeneous COVID-19 Severity

dc.contributor.authorKaraderi, Tugce
dc.contributor.authorBareke, Halin
dc.contributor.authorKunter, Imge
dc.contributor.authorSeytanoglu, Adil
dc.contributor.authorCagnan, Ilgin
dc.contributor.authorBalci, Deniz
dc.contributor.authorTaneri, Bahar
dc.date.accessioned2026-02-06T18:23:54Z
dc.date.issued2020
dc.departmentDoğu Akdeniz Üniversitesi
dc.description.abstractCOVID-19 presentation is very heterogeneous across cases, and host factors are at the forefront for the variables affecting the disease manifestation. The immune system has emerged as a key determinant in shaping the outcome of SARS-CoV-2 infection. It is mainly the deleterious unconstrained immune response, rather than the virus itself, which leads to severe cases of COVID-19 and the associated mortality. Genetic susceptibility to dysregulated immune response is highly likely to be among the host factors for adverse disease outcome. Given that such genetic susceptibility has also been observed in autoimmune diseases (ADs), a number of critical questions remain unanswered; whether individuals with ADs have a significantly different risk for COVID-19-related complications compared to the general population, and whether studies on the genetics of ADs can shed some light on the host factors in COVID-19. In this perspective, we discuss the host genetic factors, which have been under investigation in association with COVID-19 severity. We touch upon the intricate link between autoimmunity and COVID-19 pathophysiology. We put forth a number of autoimmune susceptibility genes, which have the potential to be additional host genetic factors for modifying the severity of COVID-19 presentation. In summary, host genetics at the intersection of ADs and COVID-19 may serve as a source for understanding the heterogeneity of COVID-19 severity, and hence, potentially holds a key in achieving effective strategies in risk group identification, as well as effective treatments.
dc.description.sponsorshipNovo Nordisk Foundation Center for Protein Research [NNF14CC0001]; National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust; Novo Nordisk Foundation Center for Protein Research [PI Søren Brunak] Funding Source: researchfish
dc.description.sponsorshipTK was supported by the Novo Nordisk Foundation Center for Protein Research (grant NNF14CC0001). MBH was supported by the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. The views expressed are those of the author and not necessarily those of the NIHR or the Department of Health and Social Care.
dc.identifier.doi10.3389/fimmu.2020.586111
dc.identifier.issn1664-3224
dc.identifier.orcid0000-0001-9763-8139
dc.identifier.orcid0000-0002-5169-8571
dc.identifier.orcid0000-0003-1417-7117
dc.identifier.orcid0000-0002-9087-4638
dc.identifier.orcid0000-0001-5706-306X
dc.identifier.pmid33414783
dc.identifier.scopus2-s2.0-85099055959
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3389/fimmu.2020.586111
dc.identifier.urihttps://hdl.handle.net/11129/9965
dc.identifier.volume11
dc.identifier.wosWOS:000604606900001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers in Immunology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260204
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectimmune response
dc.subjectautoimmunity
dc.subjecthost genetics
dc.subjectsusceptibility
dc.subjectcytokine
dc.subjectpolymorphism
dc.titleHost Genetics at the Intersection of Autoimmunity and COVID-19: A Potential Key for Heterogeneous COVID-19 Severity
dc.typeArticle

Files